Parkman Healthcare Partners LLC Has $2.25 Million Stock Holdings in InspireMD, Inc. (NYSE:NSPR)

Parkman Healthcare Partners LLC lifted its holdings in InspireMD, Inc. (NYSE:NSPR - Free Report) by 721.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 854,716 shares of the company's stock after purchasing an additional 750,635 shares during the quarter. Parkman Healthcare Partners LLC owned about 3.28% of InspireMD worth $2,248,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Renaissance Technologies LLC bought a new stake in InspireMD in the 4th quarter valued at approximately $27,000. Essex Investment Management Co. LLC bought a new stake in InspireMD in the 4th quarter valued at approximately $191,000. Affiance Financial LLC lifted its stake in InspireMD by 2.9% in the 4th quarter. Affiance Financial LLC now owns 189,122 shares of the company's stock valued at $497,000 after acquiring an additional 5,376 shares in the last quarter. Legato Capital Management LLC bought a new stake in InspireMD in the 4th quarter valued at approximately $47,000. Finally, Northern Trust Corp lifted its stake in InspireMD by 103.7% in the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company's stock valued at $126,000 after acquiring an additional 24,452 shares in the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Trading Down 5.8%

NSPR opened at $2.43 on Wednesday. InspireMD, Inc. has a 1-year low of $2.07 and a 1-year high of $3.80. The stock's fifty day simple moving average is $2.64 and its 200 day simple moving average is $2.74. The stock has a market cap of $74.44 million, a PE ratio of -3.24 and a beta of 0.62.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. StockNews.com assumed coverage on InspireMD in a research note on Monday, May 5th. They set a "sell" rating on the stock. Piper Sandler dropped their price objective on InspireMD from $4.50 to $4.00 and set an "overweight" rating on the stock in a research note on Monday.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.